Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab
Status: | Recruiting |
---|---|
Conditions: | Lymphoma, Hematology |
Therapuetic Areas: | Hematology, Oncology |
Healthy: | No |
Age Range: | Any |
Updated: | 4/6/2019 |
Start Date: | December 29, 2017 |
End Date: | November 2020 |
Contact: | Akshay Sudhindra, MD |
Email: | clinicalstudies@atarabio.com |
Phone: | 805-409-7653 |
Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab
This is a multicenter, open label, single-arm, phase 3 study to assess the efficacy and
safety of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant
lymphoproliferative disease (EBV+ PTLD) in the setting of allogeneic hematopoietic cell
transplant (HCT) after failure of rituximab.
safety of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant
lymphoproliferative disease (EBV+ PTLD) in the setting of allogeneic hematopoietic cell
transplant (HCT) after failure of rituximab.
This is a multicenter, open label, single-arm, phase 3 study to assess the efficacy and
safety of tabelecleucel for the treatment of EBV+ PTLD in the setting of allogeneic HCT after
failure of rituximab.
Tabelecleucel will be selected for the subject from the bank of available tabelecleucel cell
products based on matching >= 2 human leukocyte antigen (HLA) alleles, at least one of which
is a restricting HLA allele, shared between the tabelecleucel donor and the subject's EBV+
PTLD. Sites will provide high resolution subject and subject's graft donor HLA typing results
and other information as required by the protocol.
Tabelecleucel will be administered in cycles lasting 5 weeks (35 days). During each cycle,
subjects will receive intravenous (IV) tabelecleucel at a dose of 2×10^6 cells/kg on Days 1,
8, and 15, followed by observation through Day 35.
safety of tabelecleucel for the treatment of EBV+ PTLD in the setting of allogeneic HCT after
failure of rituximab.
Tabelecleucel will be selected for the subject from the bank of available tabelecleucel cell
products based on matching >= 2 human leukocyte antigen (HLA) alleles, at least one of which
is a restricting HLA allele, shared between the tabelecleucel donor and the subject's EBV+
PTLD. Sites will provide high resolution subject and subject's graft donor HLA typing results
and other information as required by the protocol.
Tabelecleucel will be administered in cycles lasting 5 weeks (35 days). During each cycle,
subjects will receive intravenous (IV) tabelecleucel at a dose of 2×10^6 cells/kg on Days 1,
8, and 15, followed by observation through Day 35.
Inclusion Criteria:
1. Prior allogeneic hematopoietic cell transplant
2. A diagnosis of locally-assessed, biopsy-proven EBV+ PTLD with a pathology sample
available for central review
3. Availability of appropriate partially HLA-matched and restricted tabelecleucel cell
product
4. Measurable, 18F-deoxyglucose (FDG)-avid (Deauville score >= 3) systemic disease (using
Lugano Classification response criteria) by positron emission tomography
(PET)-diagnostic computed tomography (CT). Baseline scans must be of acceptable
quality to the central radiology laboratory prior to Cycle 1 Day 1.
5. Failure of rituximab for first-line treatment of PTLD. Note: Subjects with CD20
negative disease are eligible to enroll without prior anti-CD20 therapy after failure
of first-line treatment (reduction of immunosuppression is not considered first-line
therapy) and discussion with the sponsor's medical monitor.
6. Males and females of any age
7. Eastern Cooperative Oncology Group (ECOG) performance status <= 3 for subjects aged >
16 years; Lansky score >= 20 for subjects from birth to 16 years
8. Underlying primary disease, for which the subject underwent transplant, is in
morphologic remission
9. Adequate organ function
1. Absolute neutrophil count >= 500/µL, with or without cytokine support
2. Platelet count >= 50,000/µL, with or without transfusion support; platelet count
< 50,000/µL but >= 20,000/µL, with or without transfusion support, is permissible
if the subject has not had Grade >= 2 bleeding in the prior 6 months (where
grading of the bleeding is determined per the National Cancer Institute's Common
Terminology Criteria for Adverse Events [CTCAE], version 5.0)
3. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total
bilirubin (TBILI) each < 3 x the upper limit of normal (ULN); however, ALT, AST,
and TBILI each <= 5 x ULN is acceptable if the elevation is considered by the
investigator to be due to PTLD involvement of the liver
4. Creatinine < 3 x ULN
10. Subject or subject's representative is willing and able to provide written informed
consent
Exclusion Criteria:
1. Daily steroids of > 0.5 mg/kg prednisone or glucocorticoid equivalent, methotrexate,
or extracorporeal photopheresis
2. History of central nervous system (CNS) PTLD
3. Grade >= 2 graft-versus-host disease (GvHD) per the Center for International Blood and
Marrow Transplant Research (CIBMTR) consensus grading system at enrollment
4. Ongoing or recent use of a checkpoint inhibitor (eg, nivolumab, pembrolizumab,
ipilimumab) within three drug half-lives from the most recent dose to Cycle 1 Day 1
5. Active adenovirus viremia
6. Need for vasopressor or ventilatory support
7. Antithymocyte globulin or similar anti-T cell antibody therapy <= 4 weeks prior to
Cycle 1 Day 1
8. Treatment with Epstein-Barr virus cytotoxic T lymphocytes, chimeric antigen receptor
(CAR)-T cells directed against B cells, or unselected donor lymphocyte infusion (DLI)
within 8 weeks of Cycle 1 Day 1
9. Pregnancy
10. Female of childbearing potential or male with a female partner of childbearing
potential unwilling to use a highly effective method of contraception
11. Inability to comply with study-related procedures
We found this trial at
16
sites
Saint Louis, Missouri 63110
Phone: 314-747-8439
Click here to add this to my saved trials
2220 Pierce Ave
Nashville, Tennessee 37232
Nashville, Tennessee 37232
615-936-8422
Phone: 615-875-6138
Vanderbilt-Ingram Cancer Center The Vanderbilt-Ingram Cancer Center, located in Nashville, Tenn., brings together the clinical...
Click here to add this to my saved trials
Atlanta, Georgia 30322
Phone: 404-727-4995
Click here to add this to my saved trials
13123 E 16th Ave
Aurora, Colorado 80045
Aurora, Colorado 80045
(720) 777-1234
Phone: 720-777-4733
Children's Hospital Colorado At Children's Hospital Colorado, we see more, treat more and heal more...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Chicago, Illinois 60611
Phone: 312-227-4090
Click here to add this to my saved trials
Houston, Texas 77030
Phone: 713-792-6620
Click here to add this to my saved trials
Maywood, Illinois 60153
Phone: 708-327-3148
Click here to add this to my saved trials
Memphis, Tennessee 38105
Phone: 901-595-4720
Click here to add this to my saved trials
Miami, Florida 33136
Phone: 305-243-6626
Click here to add this to my saved trials
New York, New York 10065
Phone: 212-639-6715
Click here to add this to my saved trials
Click here to add this to my saved trials
Portland, Oregon 97239
Phone: 503-494-0829
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials